Orient Pharma Co., Ltd. (4166.TWO)
TWD 37.1
(-2.5%)
TWD 37.1
(-2.5%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -102.99 Million | 11.38 Million | -53.56 Million | -147.95 Million | -129.9 Million |
| Net Income | 22.92 Million | -41.1 Million | -110.09 Million | -165.64 Million | -201.02 Million |
| Depreciation & Amortization | 135.57 Million | 69.1 Million | 65.17 Million | 66.56 Million | 63.84 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | 136 Thousand | 1.97 Million | 4.64 Million |
| Change in working capital | -269.26 Million | -40.24 Million | -22.1 Million | -61.87 Million | -17.25 Million |
| Other non-cash items | 27.53 Million | 9.33 Million | 9.76 Million | 19.17 Million | 19.88 Million |
| Investing Cash Flow | -88.01 Million | -29.08 Million | 55.8 Million | -194.59 Million | 15.7 Million |
| Investments in PPE | -73.51 Million | -28.92 Million | -69.99 Million | -74.42 Million | -25.39 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -9 Million | - | 120 Million | -120 Million | - |
| Sales/Maturities of investments | 20.8 Million | - | - | 41.6 Million | 91.6 Million |
| Other Investing Activities | -5.5 Million | -424 Thousand | 5.8 Million | -170 Thousand | 41.1 Million |
| Financing Cash Flow | 197.89 Million | -36.79 Million | 79.1 Million | 354.85 Million | 94.55 Million |
| Debt repayment | -215.9 Million | -25.75 Million | -89.03 Million | -36.6 Million | -35.13 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 400 Million | 3.92 Million |
| Other Financing Activities | 246 Million | -93 Million | -1.6 Million | 376.5 Million | 59.41 Million |
| Accounts receivables | -95.36 Million | -6.3 Million | 15.11 Million | -11.03 Million | -2.4 Million |
| Accounts payables | -6.36 Million | - | - | - | - |
| Inventory | -43.67 Million | -62.22 Million | -25.38 Million | -36.33 Million | -27.26 Million |
| Other working capital | -80.99 Million | -1.14 Million | -36.16 Million | -2.74 Million | 12.41 Million |
| Cash at beginning of period | 76.43 Million | 130.92 Million | 49.58 Million | 37.3 Million | 56.94 Million |
| Cash at end of period | 83.31 Million | 76.43 Million | 130.92 Million | 49.58 Million | 37.3 Million |
| Capital Expenditure | -73.51 Million | -28.92 Million | -69.99 Million | -74.42 Million | -25.39 Million |
| Effect of forex changes on cash | - | 1000.00 | -3000.00 | -29 Thousand | - |
| Net cash flow / Change in cash | 6.88 Million | -54.49 Million | 81.34 Million | 12.27 Million | -19.63 Million |
| Free Cash Flow | -176.5 Million | -17.53 Million | -123.56 Million | -222.38 Million | -155.3 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 48.5 Million | 48.5 Million | 11.04 Million | 22.92 Million | 11.04 Million | 101.5 Thousand |
| Depreciation & Amortization | 34.24 Million | 34.24 Million | 33.87 Million | 135.57 Million | 33.87 Million | 33.29 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -46.82 Million | -46.82 Million | -42.49 Million | -269.26 Million | -42.49 Million | -67.52 Million |
| Other non-cash items | 33.01 Million | 33.01 Million | 14 Million | 27.53 Million | 14 Million | -33.8 Million |
| Investing Cash Flow | -6.15 Million | -6.15 Million | -13.31 Million | -88.01 Million | -13.31 Million | -30.68 Million |
| Investments in PPE | -6.46 Million | -6.46 Million | -6.34 Million | -73.51 Million | -6.34 Million | -20.71 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -9 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 312.5 Thousand | 312.5 Thousand | -6.97 Million | -5.5 Million | -6.97 Million | -9.97 Million |
| Financing Cash Flow | -29.07 Million | -29.07 Million | -6.53 Million | 197.89 Million | -6.53 Million | 105.48 Million |
| Debt repayment | - | - | - | -215.9 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -29.07 Million | -29.07 Million | -6.53 Million | 246 Million | -6.53 Million | 105.48 Million |
| Accounts receivables | -17.09 Million | -17.09 Million | 7.29 Million | -95.36 Million | 7.29 Million | -54.97 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -20.7 Million | -20.7 Million | -17.94 Million | -43.67 Million | -17.94 Million | -3.88 Million |
| Other working capital | -9.02 Million | -9.02 Million | -31.83 Million | -80.99 Million | -31.83 Million | -8.65 Million |
| Cash at beginning of period | - | - | - | 76.43 Million | - | - |
| Cash at end of period | 33.71 Million | 33.71 Million | -3.42 Million | 83.31 Million | -3.42 Million | 6.86 Million |
| Capital Expenditure | -6.46 Million | -6.46 Million | -6.34 Million | -73.51 Million | -6.34 Million | -20.71 Million |
| Effect of forex changes on cash | 1000.00 | 1000.00 | -500.00 | - | -500.00 | 500.00 |
| Net cash flow / Change in cash | 33.71 Million | 33.71 Million | -3.42 Million | 6.88 Million | -3.42 Million | 6.86 Million |
| Free Cash Flow | 62.47 Million | 62.47 Million | 10.08 Million | -176.5 Million | 10.08 Million | -88.63 Million |
NATR
RPL
1729
HMU
300725
NCRBF